October 15, 2024 02:08 PM EDT

J&J’s medtech slump continues, improvements not expected until 2025

Max Bayer

Pharma Reporter

Johnson & Johnson beat investors’ expectations despite its medtech unit underperforming, with execs pointing to the Asia-Pacific region as a continued source of struggle. …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

J&J’s medtech slump continues, improvements not expected until 2025

Max Bayer

Pharma Reporter

Sign up to read this article for free.

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Pharma companies rush in to buy what they hope will rival Keytruda

Agenus quickly exits CDMO business by selling assets to Zydus for $75M upfront

New CBER chief Prasad promises to 'rapidly' push even small advances for rare disease drugs

Canid raises $10M to manage vaccines for pediatricians

At ASCO, cell therapies for deadly form of brain cancer make early strides

Cytiva and EurekaBio form strategic partnership to advance lentiviral vector manufacturing for cell and gene therapy ...

J&J’s medtech slump con­tin­ues, im­prove­ments not ex­pect­ed un­til 2025

Pharma Reporter

Sign up to read this article for free.

Autonomy Bio Inc.

San Francisco, CA 94107, USA

J&J’s medtech slump continues, improvements not expected until 2025